Urgent.News

One page, thousands of outlets. See who else covered it.

Editions

Health & Medicine

BioMarin does another small deal to get early-stage bone disease asset

A week after ending development of a rare disease drug from a $270 million acquisition, BioMarin is back at the dealmaking table for a very similar number. The California biopharma

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Tuesday 18 August →